Humana (NYSE:HUM) Releases Earnings Results, Beats Estimates By $1.11 EPS

Humana (NYSE:HUM) issued its quarterly earnings data on Wednesday. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11, RTT News reports. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter in the previous year, the firm earned $9.38 EPS. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. Humana updated its FY24 guidance to approx. $16.00 EPS.

Humana Stock Performance

HUM opened at $311.41 on Friday. The company has a quick ratio of 1.59, a current ratio of 1.67 and a debt-to-equity ratio of 0.77. The company has a market cap of $37.57 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 1.85 and a beta of 0.45. Humana has a 52-week low of $299.23 and a 52-week high of $541.21. The firm’s fifty day simple moving average is $328.56 and its two-hundred day simple moving average is $395.71.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.14%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Insider Buying and Selling at Humana

In related news, Director Jorge S. Mesquita acquired 545 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were acquired at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HUM. Jefferies Financial Group cut their price objective on shares of Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a research report on Monday. Raymond James began coverage on shares of Humana in a research report on Friday, March 22nd. They set a “market perform” rating on the stock. TD Cowen dropped their target price on shares of Humana from $427.00 to $396.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Deutsche Bank Aktiengesellschaft downgraded shares of Humana from a “buy” rating to a “hold” rating and dropped their target price for the stock from $595.00 to $360.00 in a research report on Thursday, January 25th. Finally, Wells Fargo & Company dropped their target price on shares of Humana from $413.00 to $350.00 and set an “overweight” rating on the stock in a research report on Monday, April 8th. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $433.74.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.